Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb 1;2(2):CD008983.
doi: 10.1002/14651858.CD008983.pub3.

Influenza vaccines in immunosuppressed adults with cancer

Roni Bitterman  1 , Noa Eliakim-Raz, Inbal Vinograd, Anca Zalmanovici Trestioreanu, Leonard Leibovici, Mical Paul
Affiliations

Influenza vaccines in immunosuppressed adults with cancer

Roni Bitterman et al. Cochrane Database Syst Rev. .

Abstract

Background: This is an update of the Cochrane review published in 2013, Issue 10.Immunosuppressed cancer patients are at increased risk of serious influenza-related complications. Guidelines, therefore, recommend influenza vaccination for these patients. However, data on vaccine effectiveness in this population are lacking, and the value of vaccination in this population remains unclear.

Objectives: To assess the effectiveness of influenza vaccine in immunosuppressed adults with malignancies. The primary review outcome is all-cause mortality, preferably at the end of the influenza season. Influenza-like illness (ILI, a clinical definition), confirmed influenza, pneumonia, any hospitalisations, influenza-related mortality and immunogenicity were defined as secondary outcomes.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and LILACS databases up to May 2017. We searched the following conference proceedings: ICAAC, ECCMID, IDSA (infectious disease conferences), ASH, ASBMT, EBMT (haematological), and ASCO (oncological) between the years 2006 to 2017. In addition, we scanned the references of all identified studies and pertinent reviews. We searched the websites of the manufacturers of influenza vaccine. Finally, we searched for ongoing or unpublished trials in clinical trial registry databases.

Selection criteria: Randomised controlled trials (RCTs), prospective and retrospective cohort studies and case-control studies were considered, comparing inactivated influenza vaccines versus placebo, no vaccination or a different vaccine, in adults (16 years and over) with cancer. We considered solid malignancies treated with chemotherapy, haematological cancer patients treated or not treated with chemotherapy, cancer patients post-autologous (up to six months after transplantation) or allogeneic (at any time) haematopoietic stem cell transplantation (HSCT).

Data collection and analysis: Two review authors independently assessed the risk of bias and extracted data from included studies adhering to Cochrane methodology. Meta-analysis could not be performed because of different outcome and denominator definitions in the included studies.

Main results: We identified six studies with a total of 2275 participants: five studies comparing vaccination with no vaccination, and one comparing adjuvanted vaccine with non-adjuvanted vaccine. Three studies were RCTs, one was a prospective observational cohort study and two were retrospective cohort studies.For the comparison of vaccination with no vaccination we included two RCTs and three observational studies, including 2202 participants. One study reported results in person-years while the others reported results per person. The five studies were performed between 1993 and 2015 and included adults with haematological diseases (three studies), patients following bone marrow transplantation (BMT) (two studies) and solid malignancies (three studies).One RCT and two observational studies reported all-cause mortality; the RCT showed similar mortality rates in both arms (odds ratio (OR) 1.25 (95% CI 0.43 to 3.62; 1 study, 78 participants, low-certainty evidence)); and the observational studies demonstrated a significant association between vaccine receipt and lower risk of death, adjusted hazard ratio 0.88 (95% CI 0.78 to 1; 1 study, 1577 participants, very low-certainty evidence) in one study and OR 0.42 (95% CI 0.24 to 0.75; 1 study, 806 participants, very low-certainty evidence) in the other. One RCT reported a reduction in ILI with vaccination, while no difference was observed in one observational study. Confirmed influenza rates were lower with vaccination in one RCT and the three observational studies, the difference reaching statistical significance in one. Pneumonia was observed significantly less frequently with vaccination in one observational study, but no difference was detected in another or in the RCT. One RCT showed a reduction in hospitalisations following vaccination, while an observational study found no difference. No life-threatening or persistent adverse effects from vaccination were reported. The strength of evidence was limited by the low number of included studies and by their low methodological quality and the certainty of the evidence for the mortality outcome according to GRADE was low to very low.For the comparison of adjuvanted vaccine with non-adjuvanted vaccine, we identified one RCT, including 73 patients. No differences were found for the primary and all secondary outcomes assessed. Mortality risk ratio was 0.54 (95% CI 0.05 to 5.73; low-certainty evidence) in the adjuvanted vaccine group. The quality of evidence was low due to the small sample size and the large confidence intervals for all outcomes.

Authors' conclusions: Observational data suggest lower mortality and infection-related outcomes with influenza vaccination. The strength of evidence is limited by the small number of studies and low grade of evidence. It seems that the evidence, although weak, shows that the benefits overweigh the potential risks when vaccinating adults with cancer against influenza. However, additional placebo or no-treatment controlled RCTs of influenza vaccination among adults with cancer is ethically questionable.There is no conclusive evidence regarding the use of adjuvanted versus non-adjuvanted influenza vaccine in this population.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Influenza vaccine versus none, Outcome 1 All‐cause mortality.
1.2
1.2. Analysis
Comparison 1 Influenza vaccine versus none, Outcome 2 Influenza‐like illness.
1.3
1.3. Analysis
Comparison 1 Influenza vaccine versus none, Outcome 3 Confirmed influenza.
1.4
1.4. Analysis
Comparison 1 Influenza vaccine versus none, Outcome 4 Pneumonia.
1.5
1.5. Analysis
Comparison 1 Influenza vaccine versus none, Outcome 5 Any hospitalisation.
1.6
1.6. Analysis
Comparison 1 Influenza vaccine versus none, Outcome 6 Influenza‐related mortality.
2.1
2.1. Analysis
Comparison 2 Adjuvanted vaccine versus non‐adjuvanted vaccine, Outcome 1 All‐cause mortality.
2.2
2.2. Analysis
Comparison 2 Adjuvanted vaccine versus non‐adjuvanted vaccine, Outcome 2 Confirmed influenza.
2.3
2.3. Analysis
Comparison 2 Adjuvanted vaccine versus non‐adjuvanted vaccine, Outcome 3 Any hospitalisation.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Ambati 2015 {published data only}
    1. Ambati A, Boas LSV, Ljungman P, Testa L, Oliveira JF, Aoun M, et al. Evaluation of pretransplant influenza vaccination in hematopoietic SCT: a randomized prospective study. Bone Marrow Transplantation 2015;50:858‐64. - PubMed
Earle 2003 {published data only}
    1. Earle CC. Influenza vaccination in elderly patients with advanced colorectal cancer. Journal of Clinical Oncology 2003;21(6):1161‐6. - PubMed
Machado 2005 {published data only}
    1. Machado CM, Cardoso MRA, Rocha IF, Boas LSV, Dulley FL, Pannuti CS. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplantation 2005;36:897‐900. - PubMed
Musto 1997 {published data only}
    1. Musto P, Carotenuto M. Vaccination against influenza in multiple myeloma. British Journal of Haematology 1997;97(2):504‐10. - PubMed
Natori 2017 {published data only}
    1. Natori Y, Humar A, Lipton J, Kim DD, Ashton P, Hoschler K, et al. A pilot randomized trial of adjuvanted influenza vaccine in adult allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation 2017;52:1016‐21. - PubMed
Vinograd 2013 {published data only}
    1. Vinograd I, Eliakim‐Raz N, Farbman L, Baslo R, Taha A, Sakhnini A, et al. Clinical effectiveness of seasonal influenza vaccine among adult cancer patients. Cancer 2013;119(22):4028‐35. [10.1002/cncr.28351] - PubMed

References to studies excluded from this review

Adell 2002 {published data only}
    1. Adell C, Bayas JM, Vilella A, Perales M, Vidal J, Bertran MJ, et al. Post‐transplantation vaccination of bone‐marrow transplant recipients [Vacunacion de pacientes receptores de trasplante de progenitores hematopoyeticos]. Medicina Clinica Journal 2002;119(11):405‐9. - PubMed
Anderson 1999 {published data only}
    1. Anderson H, Petrie K, Berrisford C, Charlett A, Thatcher N, Zambon M. Seroconversion after influenza vaccination in patients with lung cancer. British Journal of Cancer 1999;80:219‐20. - PMC - PubMed
Avetisyan 2008 {published data only}
    1. Avetisyan G, Aschan J, Hassan M, Ljungman P. Evaluation of immune responses to seasonal influenza vaccination in healthy volunteers and in patients after stem cell transplantation. Transplantation 2008;86(2):257‐63. - PubMed
Ayoola 2016 {published data only}
    1. Ayoola A, Sukumaran S, Kumar R, Gordon D, Roy A, Vantandoust S, et al. Efficacy of influenza vaccine (FluVax) in patients on chemotherapy (POCT): final data analysis from South Australia. 41st European Society for Medical Oncology Congress, ESMO 2016. 2016.
Baluch 2013 {published data only}
    1. Baluch A, Humar A, Eurich D, Egli A, Liacini A, Hoschler K, et al. Randomized controlled trial of high‐dose intradermal versus standard‐dose intramuscular influenza vaccine in organ transplant recipients. American Journal of Transplantation 2013;13(4):1026‐33. - PubMed
Bedognetti 2009 {published data only}
    1. Bedognetti D, Zoppoli G, Massucco C, Zupo S, Sertoli MR. Impaired humoral response to influenza vaccine and prolonged B memory cell depletion as a consequence of rituximab‐based immunochemotherapy in non‐hodgkin lymphoma patients. Journal of Immunotherapy 2009;32(9):992–3.
Bedognetti 2010 {published data only}
    1. Bedognetti D, Zoppoli G, Zanardi E, Massucco C, Sertoli MR. Prolonged lack of humoral response to influenza vaccine associated with a persistent depletion of B memory cells in non‐hodgkin’s lymphoma patients treated with rituximab‐containing immunochemotherapy. Clinical Immunology 2010;135:84.
Branagan 2015 {published data only}
    1. Branagan AR, Duffy E, Boddupall CS, Albrecht RA, Zhang L, Verma R, et al. Fluzone high‐dose influenza vaccine with a booster Is associated with low rates of iInfluenza infection in patients with plasma cell disorders. 57th Annual Meeting of the American Society of Hematology, ASH 2015. 2015.
Branagan 2016 {published data only}
    1. Branagan AR, Duffy E, Parker TL, Seropian S, Foster C, Zhang L, et al. Lower rates of influenza infection following two dose series of high dose vaccination in plasma cell disorders: results of a randomized, double‐blind, placebo‐assisted clinical trial. 58th Annual Meeting of the American Society of Hematology, ASH 2016. 2016.
Branagan 2017 {published data only}
    1. Branagan AR, Duffy E, Albrecht RA, Cooper DL, Seropian S, Parker TL, et al. Clinical and serologic responses after a two‐dose series of high‐dose influenza vaccine in plasma cell disorders: a prospective, single‐arm trial. Clinical Lymphoma, Myeloma and Leukemia 2017;17(5):296‐304. - PMC - PubMed
Brydak 1999 {published data only}
    1. Brydak LB, Calbecka M. Immunogenicity of influenza vaccine in patients with hemato‐oncological disorders. Leukemia and Lymphoma 1999;32(3‐4):369‐74. - PubMed
Brydak 2001 {published data only}
    1. Brydak LB, Guzy J, Starzyk J, Machala M, Gozdz SS. Humoral immune response after vaccination against influenza in patients with breast cancer. Support Care Cancer 2001;9(1):65‐8. - PubMed
Brydak 2006 {published data only}
    1. Brydak LB, Machala M, Centkowski P, Warzocha K, Bilinski P. Humoral response to hemagglutinin components of influenza vaccine inpatients with non‐Hodgkin malignant lymphoma. Vaccine 2006;24:6620‐23. - PubMed
Buccalosi 1995 {published data only}
    1. Bucalossi A, Marotta G, Galieni P, Bigazzi C, Valenzin PE, Dispensa E. Immunological response to influenza virus vaccine in B‐cell chronic lymphocytic leukaemia patients. Acta Haematologica 1995;93(1):56. - PubMed
Centkowski 2007 {published data only}
    1. Centkowski P, Brydak L, Machala M, Kalinka‐Warzocha E, Blasinska‐Morawiec M, Federowicz I, et al. Immunogenicity of influenza vaccination in patients with non‐Hodgkin lymphoma. Journal of Clinical Immunology 2007;27(3):339‐46. - PubMed
Chadha 2009 {published data only}
    1. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M. Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. Journal of Clinical Oncology 2009;27:e20575.
De Lavallade 2011 {published data only}
    1. Lavallade H, Garland P, Sekine T, Hoschler K, Marin D, Stringaris K, et al. Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica 2011;96(2):307‐14. - PMC - PubMed
Dhedin 2014 {published data only}
    1. Dhédin N, Krivine A, Corre N, Mallet A, Lioure B, Bay JO, et al. Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients. Vaccine 2014;32(5):585‐91. - PMC - PubMed
Engelhard 1993 {published data only}
    1. Engelhard D, Nagler A, Hardan I, Morag A, Aker M, Baciu H, et al. Antibody response to a two‐dose regimen of influenza vaccine in allogeneic T cell depleted and autologous BMT recipients. Bone Marrow Transplant 1993;11(1):1‐5. - PubMed
Feery 1977 {published data only}
    1. Feery BJ, Sullivan JR, Hurley TH, Evered MG. Immunization with influenza vaccine in patients with haematological malignant disease. Medical Journal of Australia 1977;1:292‐4. - PubMed
Ganz 1978 {published data only}
    1. Ganz PA, Shanley JD, Cherry JD. Responses of patients with neoplastic diseases to influenza virus vaccine. Cancer 1978;42:2244–7. - PubMed
Gribabis 1994 {published data only}
    1. Gribabis DA, Panayiotidis P, Boussiotis VA, Hannoun C, Pangalis GA. Influenza virus vaccine in B‐cell chronic lymphocytic leukaemia patients. Acta Haematologica 1994;91(3):115‐8. - PubMed
Hahn 2015 {published data only}
    1. Hahn M, Schnitzler P, Schweiger B, Kunz C, Ho AD, Goldschmidt H, et al. Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica 2015;100(7):e285‐8. - PMC - PubMed
Hodges 1979 {published data only}
    1. Hodges GR, Davis JW, Lewis HD Jr, Whittier FC Jr, Siegel CD, Chinn TD, et al. Response to influenza A vaccine among high‐risk patients. Southern Medical Journal 1979;72(1):29–32. - PubMed
Issa 2011 {published data only}
    1. Issa NC, Marty FM, Gagne LS, Koo S, Verrill KA, Alvea EP, et al. Seroprotectivetiters against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biological Blood MarrowTransplant 2011;17(3):434–8. - PMC - PubMed
Jamshed 2016 {published data only}
    1. Jamshed S, Walsh EE, Dimitroff LJ, Santelli JS, Falsey AR. Improved immunogenicity of high‐dose influenza vaccine compared to standard‐dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: A pilot randomized clinical trial. Vaccine 2016;34(5):630‐5. - PubMed
Jo 2009 {published data only}
    1. Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, et al. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer. Journal of Medical Virology 2009;81(4):722‐7. - PubMed
Keam 2017 {published data only}
    1. Keam B, Kim MK, Choi Y, Choi SJ, Choe PG, Lee KH, et al. Optimal timing of influenza vaccination during 3‐week cytotoxic chemotherapy cycles. Cancer 2017;123(5):841‐8. - PubMed
Lachenal 2010 {published data only}
    1. Lachenal F, Sebban C, Duruisseaux M, Biron P, Blay JY, Ghesquières H. Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center. Bulletin du Cancer 2010;97(4):E33‐6. - PubMed
Lankes 2009 {published data only}
    1. Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC. Vaccination history and risk of non‐Hodgkin lymphoma: a population‐based, case‐control study. Cancer Causes and Control 2009;20(5):517‐23. - PMC - PubMed
Ljungman 2005 {published data only}
    1. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study. British Journal of Haematology 2005;130(1):96‐8. - PubMed
Ljungman 2015 {published data only}
    1. Ambati A, Einarsdottir S, Magalhaes I, Poiret T, Bodenstein R, LeBlanc K, et al. Immunogenicity of virosomal adjuvanted trivalent influenza vaccination in allogeneic stem cell transplant recipients. Transplant Infectious Disease 2015;17(3):371‐9. - PubMed
Lo 1993 {published data only}
    1. Lo W, Whimbey E, Elting L, Couch R, Cabanillas F, Bodey G. Antibody response to a two‐dose influenza vaccine regimen in adult lymphoma patients on chemotherapy. European Journal of Clinical Microbiology & Infectious Diseases 1993;12(10):778‐82. - PubMed
Mazza 2005 {published data only}
    1. Mazza JJ, Yale SH, Arrowood JR, Reynolds CE, Glurich I, Chyou PH, et al. Efficacy of the influenza vaccine in patients with malignant lymphoma. Clinical Medicine and Research 2005;3(4):214‐20. - PMC - PubMed
Mulder 2009 {published data only}
    1. Mulder SF, Jacobs JFM, Olde Nordkamp MAM, Kremer IK, Mulders PFA. Immunological response to influenza vaccine in cancer patients undergoing treatment with sunitinib or sorafenib. European Journal of Cancer 2009;7:116.
Nakashima 2017 {published data only}
    1. Nakashima K, Aoshima M, Ohfuji S, Suzuki K, Katsurada M, Katsurada N, et al. Immunogenicity of trivalent influenza vaccine in patients with lung cancer undergoing anticancer chemotherapy. Human Vaccines and Immunotherapeutics 2017;13(3):543‐50. - PMC - PubMed
Nordoy 2002 {published data only}
    1. Nordoy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Medical Oncology 2002;19(2):71‐8. - PubMed
Ortbals 1977 {published data only}
    1. Ortbals DW, Liebhaber H, Presant CA, Amburg AL 3rd, Lee JY. Influenza immunization of adult patients with malignant diseases. Annals of Internal Medicine 1977;87(5):552‐7. - PubMed
Puthillath 2011 {published data only}
    1. Puthillath A, Trump DL, Andrews C, Bir A, Romano K, Wisniewski M, et al. Serological immune responses to influenza vaccine in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology 2011;67(1):111‐5. - PubMed
Rapezzi 2003 {published data only}
    1. Rapezzi D, Sticchi L, Racchi O, Mangerini R, Ferraris AM, Gaetani GF. Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. European Journal of Haematology 2003;70(4):225‐30. - PubMed
Robertson 2000 {published data only}
    1. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. British Journal of Cancer 2000;82(7):1261‐5. - PMC - PubMed
Safdar 2006 {published data only}
    1. Safdar A, Rodriguez MA, Fayad LE, Rodriguez GH, Pro B, Wang M, et al. Dose‐related safety and immunogenicity of baculovirus‐expressed trivalent influenza vaccine: a double‐blind, controlled trial in adult patients with non‐Hodgkin B cell lymphoma. Journal of Infectious Diseases 2006;194(10):1394‐7. - PubMed
Schafer 1979 {published data only}
    1. Schafer AI, Churchill WH, Ames P, Weinstein L. The influence of chemotherapy on response of patients with hematologic malignancies to influenza vaccine. Cancer 1979;43(1):25‐30. - PubMed
Seidel 2011 {published data only}
    1. Seidel A, Smith D, Yung E, Aquino L, Srivastava T, Pullarkat V, et al. CD154 expression is associated with neutralizing antibody titer levels postinfluenza vaccination in stem cell transplant patients and healthy adults. Biology of Blood and Marrow Transplantation 2011;17(4):524‐33. - PMC - PubMed
Shildt 1979 {published data only}
    1. Shildt RA, Luedke DW, Kasai G, El‐Beheri S, Laham MN. Antibody response to influenza immunization in adult patients with malignant disease. Cancer 1979;44(5):1629‐35. - PubMed
Spies 2008 {published data only}
    1. Spies CD, Kip M, Lau A, Sander M, Breuer JP, Meyerhoefer J, et al. Influence of vaccination and surgery on HLA‐DR expression in patients with upper aerodigestive tract cancer. Journal of International Medical Research 2008;36:296‐307. - PubMed
Spitaleri 2010 {published data only}
    1. Spitaleri G, Delmonte A, Toffalorio F, Pas TM, Gregorc V. Safety of concomitant administration of seasonal and/or H1N1 flu vaccination in patients receiving erlotinib for advanced non‐small cell lung cancer. Journal of Thoracic Oncology 2010;5(5):752‐4. - PubMed
Stiver 1978 {published data only}
    1. Stiver HG, Weinerman BH. Impaired serum antibody response to inactivated influenza A and B vaccine in cancer patients. Canadian Medical Association Journal 1978;119(7):733‐8. - PMC - PubMed
Sun 2016 {published data only}
    1. Sun C, Gao J, Couzens L, Tian X, Farooqui MZ, Eichelberger MC, et al. Seasonal Influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib. JAMA Oncology 2016;2(12):1656‐7. - PMC - PubMed
Takata 2009 {published data only}
    1. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non‐Hodgkin B‐cell lymphoma after the administration of rituximab‐CHOP. Journal of Clinical Experimental Hematopathology 2009;49(1):9‐13. - PubMed
Van der Velden 2001 {published data only}
    1. Velden AM, Mulder AH, Hartkamp A, Diepersloot RJ, Velzen‐Blad H, Biesma DH. Influenza virus vaccination and booster in B‐cell chronic lymphocytic leukaemia patients. European Journal of Internal Medicine 2001;12(5):420‐4. - PubMed
Villa 2013 {published data only}
    1. Villa D, Gubbay J, Sutherland DR, Laister R, McGeer A, Cooper C, et al. Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant. Leukemia and Lymphoma 2013;54(7):1387‐95. - PubMed
Wumkes 2013 {published data only}
    1. Wumkes ML, Velden AM, Los M, Leys MB, Beeker A, Nijziel MR, et al. Serum antibody response to influenza virus vaccination during chemotherapy treatment in adult patients with solid tumours. Vaccine 2013;31(52):6177‐84. - PubMed
Xu 2009 {published data only}
    1. Xu Y, Methuku N, Coimbatore P, Fitzgerald T, Huang Y, Xiao YY, et al. A prospective study of the immunogenicity of inactivated influenza A (H1N1) 2009 monovalent vaccine in patients who have solid or hematologic malignancies. 48th Annual Meeting of the Infectious Diseases Society of America, 21–24 October 2010; Vancouver, Canada. 2010; Vol. Abstract 5075, posterLB‐5013.
Yalc 2010 {published data only}
    1. Yalçin SS, Kondolot M, Albayrak N, Altaş AB, Karacan Y, Kuşkonmaz B, et al. Serological response to influenza vaccine after hematopoetic stem cell transplantation. Annals of Hematology 2010;89(9):913‐8. - PubMed

Additional references

Alistair 2002
    1. Alistair R, Gavin M, Christopher S, Peter H. Influenza vaccination and chemotherapy: a shot in the dark?. Supportive Care in Cancer 2002;10:462‐5. - PubMed
Anema 2008
    1. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C. Efficacy of influenza vaccination in HIV‐positive patients: a systematic review and meta‐analysis. HIV Medicine 2008;9(1):57‐61. - PubMed
Angelo 2004
    1. Angelo SJ, Marshall PS, Chrissoheris MP, Chaves AM. Clinical characteristics associated with poor outcome in patients acutely infected with Influenza A. Connecticut Medicine 2004;68:199‐205. - PubMed
Arrowood 2002
    1. Arrowood JR, Hayney MS. Immunization recommendations for adults with cancer. Annals of Pharmacotherapy 2002;36:1219‐29. - PubMed
Beck 2012
    1. Beck CR, McKenzie BC, Hashim AB, Harris RC, University of Nottingham Influenza and the ImmunoCompromised (UNIIC) Study Group. Influenza vaccination for immunocompromised patients: systematic review and meta‐analysis by etiology. Journal of Infectious Diseases 2012;206(8):1250‐9. - PubMed
Black 2015
    1. Black S. Safety and effectiveness of MF‐59 adjuvanted influenza vaccines in children and adults. Vaccine 2015;33(Suppl 2):B3‐5. - PubMed
Casper 2010
    1. Casper C, Englund J, Boeckh M. How I treat influenza in patients with hematologic malignancies. Blood 2010;115(7):1331‐42. - PMC - PubMed
CDC Cancer prevention 2017
    1. Centers for Disease Control and Prevention. Cancer prevention and control. Available from: http://www.cdc.gov/cancer/flu/ (accessed 19th October 2017).
CDC Flu Vaccination 2017
    1. Centers for Disease Control and Prevention. Flu Vaccination. https://www.cdc.gov/flu/professionals/vaccination/vax‐summary.htm (accessed 21st October 2017).
CDC MMWR 2010
    1. Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza ‐ United States, 1976‐2007. Morbidity and Mortality Weekly Report (MMWR) 2010 Aug 27;59(33):1057‐62. - PubMed
CDC Surveillance 2016
    1. Centers for Disease Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations, and deaths averted by vaccination in the United States. https://www.cdc.gov/flu/about/disease/2015‐16.htm (accessed 18th October 2017).
Chemaly 2006
    1. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore) 2006;85(5):278‐87. - PubMed
Chemaly 2012
    1. Chemaly RF, Vigil KJ, Saad M, Vilar‐Compte D, Cornejo‐Juarez P, Perez‐Jimenez C, et al. A multicenter study of pandemic influenza A (H1N1) infection in patients with solid tumors in 3 countries: early therapy improves outcomes. Cancer 2012;118(18):4627‐33. - PubMed
Cherif 2013
    1. Cherif H, Höglund M, Pauksens K. Adjuvanted influenza a (H1N1) 2009 vaccine in patients with hematological diseases: good safety and immunogenicity even in chemotherapy‐treated patients. European Journal of Haematology 2013;90(5):413‐9. - PubMed
Cooksley 2005
    1. Cooksley CD, Avritscher EB, Bekele BN, Rolston KV, Geraci JM, Elting LS. Epidemiology and outcomes of serious influenza‐related infections in the cancer population. Cancer 2005;104:618‐28. - PubMed
De Jong 2000
    1. Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine‐induced antibody response to this strain in the elderly. Journal of Medical Virology 2000;61(1):94‐9. - PubMed
Domnich 2017
    1. Domnich A, Arata L, Amicizia D, Puig‐Barberà J, Gasparini R, Panatto D. Effectiveness of MF59‐adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta‐analysis. Vaccine 2017;35(4):513‐20. - PubMed
Elting 1995
    1. Elting LS, Whimbey E, Lo W, Couch R, Andreeff M, Bodey GP. Epidemiology of influenza A virus infection in patients with acute or chronic leukemia. Supportive Care in Cancer 1995;3(3):198‐202. - PubMed
Engelhard 2013
    1. Engelhard D, Mohty B, Camara R, Cordonnier C, Ljungman P. European guidelines for prevention and management of influenza in hematopoietic stem cell transplantation and leukemia patients: summary of ECIL‐4 (2011), on behalf of ECIL, a joint venture of EBMT, EORTC, ICHS, and ELN. Transplant Infectious Disease 2013;15(3):219‐32. - PubMed
Fiore 2009
    1. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootrey G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports 2009;58:1‐52. - PubMed
Glezen 2008
    1. Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. New England Journal of Medicine 2008;359:2579‐85. - PubMed
Goossen 2013
    1. Goossen GM, Kremer LCM, Wetering MD. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD006484] - DOI - PMC - PubMed
Hassan 2003
    1. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem‐cell transplantation: the Christie hospital experience. Bone Marrow Transplant 2003;32(1):73‐7. - PubMed
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐ analysis. Statistics in Medicine 2002;21(11):1539‐58. - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Issa 2009
    1. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clinical Infectious Diseases 2009;48(6):772‐86. - PubMed
Jackson 2017
    1. Jackson ML, Chung JR, Jackson LA, Phillips CH, Benoit J, Monto AS, et al. Influenza vaccine effectiveness in the United States during the 2015‐2016 season. New England Journal of Medicine 2017;377(6):534‐43. - PMC - PubMed
Kamps 2006
    1. Kamps BS, Hoffmann C, Preiser W. Influenza report. http://www.influenzareport.com/influenzareport.pdf (accessed 31st December 2006).
Kunisaki 2009
    1. Kunisaki KM, Janoff EN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infectious Diseases 2009;9:493‐504. - PMC - PubMed
Langendam 2013
    1. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;23(2):81. - PMC - PubMed
Ljungman 2001
    1. Ljungman P. Respiratory virus infections in stem cell transplant patients: the European experience. Biology of Blood and Marrow Transplantation 2001;7:5S‐7S. - PubMed
Ljungman 2011
    1. Ljungman P, Camara R, Perez‐Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata‐Ortiz MJ, et al. Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation, Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem‐cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica 2011;96(8):1231‐5. - PMC - PubMed
Machado 2003
    1. Machado CM, Boas LS, Mendes AV, Santos MF, Rocha IF, Sturaro D, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplantation 2003;31(8):695‐700. - PMC - PubMed
Meader 2014
    1. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82. - PMC - PubMed
Melcher 2005
    1. Melcher L. Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. Clinical Oncology (Royal College of Radiologists) 2005;17(1):12‐5. - PubMed
Nichols 2004
    1. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clinical Infectious Diseases 2004;39(9):1300‐6. - PubMed
NOS 2010
    1. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. Newcastle Ottawa Scale (NOS) for assessing the quality of non‐randomized studies in meta‐analyses. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (accessed June 2010).
Pedrazzoli 2014
    1. Pedrazzoli P, Baldanti F, Donatelli I, Castrucci MR, Puglisi F, Silvestris N, et al. Italian Society of Medical Oncology. Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM). Annals of Oncology 2014;25(6):1243‐7. - PMC - PubMed
Pirofski 1998
    1. Pirofski LA, Casadevall A. Use of licensed vaccines for active immunization of the immunocompromised host. Clinical Microbiology Reviews 1998;11(1):1‐26. - PMC - PubMed
Redelman‐Sidi 2010
    1. Redelman‐Sidi G, Sepkowitz KA, Huang CK, Park S, Stiles J, Eagan J, et al. 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. Journal of Infection 2010;60(4):257‐63. - PubMed
Shehata 2014
    1. Shehata MA, Karim NA. Influenza vaccination in cancer patients undergoing systemic therapy. Clinical Medicine Insights. Oncology 2014;8:57‐64. - PMC - PubMed
SIGN 2010
    1. Scottish Intercollegiate Guideline Network. Search Filters, Methodology. Available from:http://www.sign.ac.uk/methodology/filters.html last modified 16 June 2010; accessed 21st June 2010.
UpToDate 2017
    1. Dolin, R. Clinical manifestations and diagnosis of seasonal influenza in adults. www.uptodate.com (accessed 18th October 2017).
Vollaard 2017
    1. Vollaard A, Schreuder I, Slok‐Raijmakers L, Opstelten W, Rimmelzwaan G, Gelderblom H. Influenza vaccination in adult patients with solid tumours treated with chemotherapy. European Journal of Cancer 2017;76:134‐43. - PubMed
WHO Influenza 2016
    1. World Health Organization. Influenza (Seasonal). Fact sheet N°211; 2016. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/ (accessed 18th October 2017).
Wiselka 1994
    1. Wiselka M. Influenza: diagnosis, management, and prophylaxis. BMJ 1994;308(6940):1341‐5. - PMC - PubMed
Yousuf 1997
    1. Yousuf HM, Englund J, Couch R, Rolston K, Luna M, Goodrich J, et al. Influenza among hospitalized adults with leukemia. Clinical Infectious Diseases 1997;24:1095‐9. - PubMed

References to other published versions of this review

Eliakim‐Raz 2013
    1. Eliakim‐Raz N, Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD008983.pub2] - DOI - PMC - PubMed
Levi‐Vinograd 2011
    1. Levi‐Vinograd I, Zalmanovici Trestioreanu A, Leibovici L, Paul M. Influenza vaccines for prevention of influenza‐like illness and influenza in immunosuppressed cancer patients. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008983] - DOI - PMC - PubMed

Publication types

MeSH terms